Why the study?
Does beta-blocker treatment improve outcomes in revascularized patients following acute myocardial infarction without reduced left ventricular ejection fraction?
Does beta-blocker treatment improve outcomes in revascularized patients following acute myocardial infarction without reduced left ventricular ejection fraction?
The BETAMI trial is designed to evaluate the clinical benefit of beta-blocker therapy in revascularized post-myocardial infarction patients with preserved ejection fraction.
No takes yet. Share an insight, caveat, or question.
BETAMI RCT will test beta-blocker benefit post-MI with preserved EF; delivers direct evidence to guide contemporary practice.
Munkhaugen et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: